A guide to care choicesCheck a licence
NevadaCare & cost guide
Explore the guide

What the quote leaves unanswered

A clear answerbeats a quick yes.

A low quote leaves the product questions open. Ask what is being prescribed, where it comes from, and what the evidence actually establishes.

Product claims

Check what the label proves

Use the actual product name when reading a claim about approval or quality.

Compounding is not an approval

FDA, the Food and Drug Administration, reviews evidence about specific medicine products and their uses.

Compounding means making a custom medicine to meet the needs of a patient.

As of September 26, 2026, no compounded medicine has FDA approval, including one from a licensed pharmacy.

Ask what prevents an approved product from meeting the medical need.

FDA · compounded medicines
Read the basis

What the source establishes

Before a custom medicine is sold, FDA does not check its quality, how well it works or its safety.

A registration or code is a different check

As of September 26, 2026, FDA registration is no proof of FDA approval for a business or any of its medicines.

A National Drug Code identifies a product; it does not show that FDA approved it.

Request the product's approval record instead of taking a registration claim as proof.

FDA · what approval means FDA · product codes
Read the basis

What the source establishes

A code in FDA's records is no proof of approval.

Pause and question a research label

FDA warns against weight-loss products sold to people under research labels, as of September 26, 2026.

These products may cause harm, and their quality remains unknown.

As of September 26, 2026, retatrutide is still a drug under study to help people lose weight.

As of September 26, 2026, FDA says pharmacies and doctors cannot legally make a custom medicine using retatrutide.

A treatment promise needs more than a research label or a product code.

FDA · research-labelled products ClinicalTrials.gov · retatrutide weight-loss research
Read the basis

What the source establishes

FDA has not established that retatrutide is safe and works for any health condition, as of September 26, 2026.

The Nevada position

Ask why a pharmacy can make its own version

When the shortages ended, the rules changed

As of September 26, 2026, FDA has approved certain semaglutide and tirzepatide products for weight loss or type 2 diabetes; approved uses are specific to each product.

Here, a copy has the same main medicine ingredient at a similar strength, taken the same way, such as by a shot.

During shortages, federal rules allowed pharmacies to make copies of certain medicines that were in short supply.

Nevada's pharmacy board issued a June 2025 notice on compounded semaglutide and tirzepatide injections.

The notice told pharmacies to stop making and supplying copies of these shots under the shortage rules, because FDA had found the shortages were over.

As of September 28, 2026, Nevada's notice still points to federal rules that allow some medicines to be made to order. For example, a medicine change may qualify if the prescriber finds that it makes a significant difference for that individual patient. The notice does not ban every medicine made to order with semaglutide.

Ask: What is different in this medicine for my health needs? Why is that change important for my care? Which rule allows the pharmacy to make it?

Nevada pharmacy board · compounding notice
Read the basis

What the source establishes

As of September 26, 2026, pharmacies and doctors face federal limits on making copies of commercially sold medicines regularly or in large amounts.

An exception applies if the prescriber finds that a change in the medicine makes a significant difference for one particular patient. The prescriber must record what was changed and why that change makes a difference for the individual patient.

Someone allergic to a dye, for instance, may need that dye left out of their medicine. A price cut by itself does not satisfy the patient-difference test.

Before using a medicine

Get the instructions from the care team

Bring the label and your questions to the prescriber or pharmacist.

Unclear measurements need an answer

FDA has reports of errors in measuring compounded semaglutide shots, as of September 26, 2026.

Some of those reports describe care in a hospital.

Ask your pharmacist to explain the label and equipment supplied with the medicine. Resolve unclear instructions with the care team before use.

FDA · reported measuring errors
Read the basis

What the source establishes

The reports include mistakes by people taking the medicine and those providing care.

When help cannot wait

Emergency care is needed for a severe allergic reaction

Signs can include trouble breathing, or a swollen tongue or face, according to MedlinePlus.

MedlinePlus · severe allergic reaction

Reporting a problem

A medicine report and a pharmacy complaint have different routes

MedWatch is FDA's free reporting service for problems with medicines; patients can submit a report themselves.

FDA · MedWatch

Nevada's pharmacy board accepts pharmacy complaints but does not handle pricing or billing disputes.

Nevada pharmacy board · complaints

Return to the decision

Put the questions beside the quote

Use the cost page to ask for a complete, written bill.

Continue